TY - JOUR T1 - Early intervention with non-invasive respiratory therapies in mild acute respiratory distress syndrome secondary to COVID-19 JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA1075 VL - 58 IS - suppl 65 SP - PA1075 AU - Sergio Suárez Escudero AU - Daniel López-Padilla AU - José Rafael Terán Tinedo AU - Virginia Parra León AU - Soledad López Martín AU - Francisco Caballero Segura AU - Christian Castro Riera AU - Alicia Cerezo Lajas AU - Elena Ojeda Castillejo AU - Beatriz Recio Moreno AU - Luis Puente Maestú Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA1075.abstract N2 - Aim: To determine the effect of early intervention with non-invasive respiratory therapies (NIRT) in COVID-19 patients with partial criteria for mild ARDS.Methods: Retrospective case-control study of COVID-19 patients during the first wave of the pandemic. Inclusion criteria were a SpO2/FiO2 score < 315 and > 235, and bilateral opacities in Chest X-ray. Controls were matched by age, sex, body mass index, Charlson comorbidity index, SpO2/FiO2 and SOFA scores pre-NIRT. Primary endpoint was a composite variable of orotracheal intubation and mortality.Results: Forty-two patients were included in the study, 14 cases and 28 controls. Table 1 presents different characteristics among both groups of study. Seven patients were treated with high flow nasal cannula (50%), and the other half with continuous positive airwat pressure. A total of 10 (23.8%) patients met the endpoint composite: 3 in the cases group (21.4%) and 7 in the control group (25%) (OR 0.82, CI95% 0.18 – 3.80).Conclusion: Early intervention with NIRT did not reduce orotracheal intubations or deaths in a group of COVID-19 patients with mild ARDS. Characteristic All patients (N=42) Cases (N=14) Controls (N=28) p-valueAge, years (SD)60.9 (11.7)60.4 (11.9)61.2 (11.7)0.84Males, %28 (66.7)9 (64.3)19 (67.9)1.00Body mass index, kg/m2 (SD)29.5 (5.6)28.7 (5.7)30.0 (5.6)0.51Charlson index (SD)1.9 (1.6)1.9 (1.3)1.9 (1.5)0.49SpO2/FiO2 pre-NIRT (SD)269.1 (18.4)272.3 (20.0)267.5 (17.7)0.43C reactive protein pre-NIRT (SD)12.9 (8.4)12.1 (8.9)13.4 (8.2)0.65SOFA score pre-NIRT (SD)3.1 (1.3)2.8 (0.9)3.2 (1.4)0.32FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA1075.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -